Product: re:Vive 2.0
Top Line: Vision diagnostics and augmentation company Heru Inc. is expanding the capabilities of re:Vive by Heru, the company’s wearable, gamified diagnostic solution, to 
include three new testing modalities: Color Vision CPT 92283, Contrast Sensitivity, and Dark Adaptation
CPT 92284.
Close Up: The new multi-modal cloud-based platform replaces several legacy devices, enabling six popular vision exams to be performed with a single, space-saving wearable at a low cost of entry. re:Vive 2.0 is a premium diagnostic tool that enables physicians to diagnose and manage more patients and provides additional avenues for reimbursement as the new testing strategies are co-billable with visual field, OCT and office visits.
“Since the inception of Heru, our goal has been to revolutionize healthcare through the development of transformative technology. With the release of these new testing modalities, Heru has created a market-leading platform that is the first of its kind. Our solution enables physicians to perform six diagnostic exams, with five revenue generating CPT codes, in one wearable platform” said Mohamed Abou Shousha, MD, PhD, CEO and founder of Heru. “These new modalities represent significant advancement in the way physicians screen and diagnose for visual disorders and highlights our dedication to delivering best-in-class technology to the market.”
Vital Stats: The re:Vive 2.0 Color Vision exam features a screening color vision test (Ishihara) and the Farnsworth D-15 extended color vision test, providing clinicians with a fast, efficient solution for detecting and classifying color vision deficiencies. If a patient fails the Ishihara test, the platform, using Heru’s AutoFlow, automatically conducts a D-15 exam, a reimbursable procedure with many supported ICD-10 codes. 
Heru’s Contrast Sensitivity exam in re:Vive 2.0 is based on the science that connects Contrast Sensitivity with the early detection of age-related macular degeneration (AMD). The test allows clinicians to show patients the subtle, often slow-changing effects of diminishing vision, and provides an efficient way to document and monitor the functional macular health. With re:Vive 2.0, Contrast Sensitivity testing is moved out of the exam lane and performed in natural room lighting without the intervention of a clinician or technician. 
The new Dark Adaptation (CPT 92284) modality found in re:Vive 2.0 enables clinicians to evaluate retinal function by measuring a patient’s dark adaptation. Impaired dark adaptation has been associated with the development of AMD and has been shown to occur prior to physiological change in the retina. 
Early diagnosis of AMD is essential in the management of this sight-threatening disease, allowing clinicians to emphasize the importance of controlling modifiable risk factors.
Heru’s re:Vive Dark Adaptation exam measures the Adaptation Index value. Our proprietary technology enables Dark Adaptation measurements using a dimmer flash brightness compared to other devices, increasing patient comfort and compliance.
“These new testing modalities are just the beginning,” said Bob George, Heru chief technology officer, who noted that the company’s new cloud-based technology will allow it to distribute future modalities over-the-air, without disrupting practice workflow.